Reuters
29 Sept 2026, 17:44 UTC · 2h ago
Verdict
Headline takes no side. We score XRS +0.60 across one claim — strongly bullish.
+0.60strongly bullish
More positive than 78% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
H Lundbeck A/S has expressed interest in acquiring Xeris Biopharma.
Newreported on Tuesday, Sep 29
More positive than 99% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 78% of ticker scores this week
The company is reported to be a target for acquisition, which typically drives share price premiums.
More positive than 57% of ticker scores this week
The company is showing strategic growth intent through a potential acquisition.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
4h ago
—
No price for XRS right now — the quote feed didn't answer.
XRS chart →
